<DOC>
	<DOC>NCT02493335</DOC>
	<brief_summary>The purpose of this study is to prove the superiority of a 48-weeks treatment with budesonide orodispersible tablets versus placebo for the maintenance of clinico-pathological remission in patients with eosinophilic esophagitis.</brief_summary>
	<brief_title>Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed informed consent, Male or female patients, 18 to 75 years of age, Confirmed clinicopathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria Clinicopathological remission of EoE, A documented trial with proton pump inhibitors (PPIs) in order to rule out PPIresponsive esophageal eosinophilia, Negative pregnancy test in females of childbearing potential at baseline visit. Clinical and endoscopic signs of gastroesophageal reflux disease (GERD), History of abnormal results in case of an optionally performed pHmonitoring of the distal esophagus, Patients with PPIresponsive esophageal eosinophilia Achalasia, scleroderma esophagus, or systemic sclerosis, Other clinically evident causes than EoE for esophageal eosinophilia, Any concomitant esophageal disease and relevant gastrointestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection [candida esophagitis]), Any relevant systemic disease (e.g., AIDS, active tuberculosis), If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection, Liver cirrhosis or portal hypertension, History of cancer in the last five years, History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit, Upper gastrointestinal bleeding within 8 weeks prior to baseline visit, Existing or intended pregnancy or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>